LEGN
Legend Biotech Corp
NASDAQ · Healthcare · Biotechnology · US
$22.54
−1.01%Price chart
Oct 7Oct 12Oct 15Oct 20Oct 23Oct 28Nov 2Nov 5
Key dataNov 5, 2026
Open$22.69
From 52W high−37.87%
Volume3.23M
Market cap$4.38B
P/E (TTM)—
P/S (TTM)3.4x
Div yield—
Key dataNov 5, 2026
Open
$22.69
From 52W high
−37.87%
Volume
3.23M
Market cap
$4.38B
ValuationView details →
P/E (Fwd)
38.6x
EV/EBITDA
1798.3x
P/E (TTM)
—
RSI (14)
68.5
MomentumView details →
1D Return
−1.01%
YTD Return
+8.04%
SummaryUpdated Jun 1, 2026
Legend Biotech Corporation (NASDAQ:LEGN) is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in Somerset, New Jersey. The company is a subsidiary of Genscript Biotech Corporation and went public in June 2020. Legend Biotech specializes in developing innovative cell therapies, particularly CAR-T (Chimeric Antigen Receptor T-cell) therapies for treating various cancers and other diseases. The company has achieved significant commercial success with its lead product CARVYKTI, which has become a leading treatment for multiple myeloma, and continues to expand its pipeline of cell therapy candidates targeting both blood cancers and solid tumors.
Similar companies
Latest newsMore news →
Legend Biotech Corp announced that it will present research on CARVYKTI and two CAR-T development programs at the 68th American Society of Hematology annual meeting in New Orleans from December 12 to 15.1d agoLegend Biotech Corp Sponsored ADR (LEGN) recently moved above its 200-day moving average.8d ago